Scott Capital Advisors LLC Purchases 151 Shares of Eli Lilly and Company (NYSE:LLY)

Scott Capital Advisors LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 30.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 651 shares of the company’s stock after buying an additional 151 shares during the period. Scott Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $493,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Gotham Asset Management LLC increased its position in shares of Eli Lilly and Company by 111.3% in the third quarter. Gotham Asset Management LLC now owns 7,386 shares of the company’s stock worth $3,967,000 after purchasing an additional 3,891 shares during the period. Advisors Asset Management Inc. increased its position in shares of Eli Lilly and Company by 0.8% in the third quarter. Advisors Asset Management Inc. now owns 75,615 shares of the company’s stock worth $40,615,000 after purchasing an additional 601 shares during the period. Axxcess Wealth Management LLC increased its position in shares of Eli Lilly and Company by 117.0% in the third quarter. Axxcess Wealth Management LLC now owns 20,916 shares of the company’s stock worth $11,235,000 after purchasing an additional 11,279 shares during the period. AXQ Capital LP bought a new position in shares of Eli Lilly and Company in the third quarter worth $1,826,000. Finally, Augustine Asset Management Inc. bought a new position in shares of Eli Lilly and Company in the third quarter worth $247,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on LLY. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Bank of America reaffirmed a “buy” rating and issued a $1,000.00 price objective on shares of Eli Lilly and Company in a research note on Monday, June 24th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Jefferies Financial Group raised their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $812.72.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold 791,145 shares of company stock worth $673,704,508 over the last ninety days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of LLY opened at $914.37 on Tuesday. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $916.83. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The company has a market capitalization of $869.03 billion, a price-to-earnings ratio of 134.66, a price-to-earnings-growth ratio of 1.97 and a beta of 0.41. The business has a 50-day moving average of $814.40 and a 200-day moving average of $740.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the company earned $1.62 earnings per share. The firm’s revenue was up 26.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.